MedTrace Logo

Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma

NCT02863055 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2025-09-19

No results posted yet for this study

Summary

This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo

Conditions

  • Malignant Pleural Mesothelioma

Interventions

DRUG

Nintedanib

Nintedanib 200 mg administered twice daily

DRUG

Placebo

Matching placebo administered twice daily

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Sanjay Popat, PhD, MD · Royal Marsden NHS Foundation Trust

  • Omar Abdel-Rahman, MD · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-04
Primary Completion
2023-10-12
Completion
2024-01-10

Countries

  • Belgium
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02863055 on ClinicalTrials.gov